Novo Nordisk's Pill Push Gathers Pace, But a Cyber Attack and Structural Risks Keep the Stock Under Pressure
13.06.2026 - 02:54:43 | boerse-global.de
Novo Nordisk has found itself at a crossroads this month. The Danish pharma group secured a coveted European approval for its oral Wegovy tablet — a landmark that opens the door to a patient population wary of injections — while simultaneously grappling with a cyber attack that exposed sensitive clinical trial data. Investors, still nursing a 45% decline from last year's all-time high of over €70, are left weighing the near-term bright spots against a darkening fundamental outlook.
The tablet’s progress cannot be ignored. In the United States, Wegovy’s oral version racked up more than 3 million prescriptions in just over five months, one of the strongest pharmaceutical launches in recent memory. Now, Britain has become the first European country to greenlight the daily GLP-1 pill, handing Novo Nordisk a strategic beachhead on the continent. France, meanwhile, has decided to reimburse obesity medications, further fuelling expectations that Europe will become a meaningful growth engine. The company plans a broader international rollout in the second half of 2026, starting with the United Arab Emirates.
That momentum, however, has been overshadowed by a cyber incident that came to light last Thursday. Attackers breached Novo Nordisk’s internal systems and copied pseudonymised patient data from clinical studies, including identification numbers, birth years and health biomarkers such as biomarkers. The company has taken some systems offline as a precaution, brought in external security experts and notified authorities. While the core business continues to run normally, the episode raises the risk of regulatory scrutiny and reputational damage — never welcome when a key product is still establishing its market credibility.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
On the stock market, the reaction has been measured. The shares closed Friday at €38.03, barely changed, and posted a modest weekly gain of around 2%. Yet that modest recovery sits atop a grim longer-term chart. Novo Nordisk’s stock has lost roughly 15% since the start of the year, driven by a profit warning in February that flagged an expected revenue decline in 2026. The pill’s commercial success and the cyber attack have done little to alter that trajectory. After hitting a low of €30.25 in March, the share price has clawed back to around €38, but it remains almost 8% below its 200-day moving average of €41.43 — a level technicians say must be reclaimed to break the downtrend.
The headwinds are not just technical. Competition in the GLP-1 space is intensifying, with Eli Lilly emerging as a formidable rival. Pricing pressure on Wegovy is mounting, and a potentially bigger threat looms in the United States: some employers are considering dropping coverage for expensive injectable obesity drugs as early as 2027. That would directly undercut future demand for Novo Nordisk’s entire portfolio.
Management is trying to cushion the blow with a multi-billion Danish krone share buyback programme. So far, it has repurchased nearly 19 million shares. But Wall Street remains cautious. Of 23 analysts polled, 18 rate the stock a Hold, and only four recommend a Buy. The wide range of price targets reflects the profound uncertainty over how quickly the oral Wegovy can offset the pressures from rivals and cost-conscious American payers.
For now, Novo Nordisk is balancing an unprecedented product opportunity against an equally unprecedented set of risks. The pill’s success in Europe and the US is real, but the cyber attack, the profit warning and the looming competitive storm mean the stock’s path to recovery is anything but straightforward.
Ad
Novo Nordisk Stock: New Analysis - 13 June
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
